Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Chemotherapy + Atezolizumab for Stage IIIa and IIIb Non-small Cell Lung Cancer Followed by Atezolizumab as Adjuvant Treatment After Surgery and Atezolizumab as Maintenance Treatment for Non-resected Patients After Chemoradiotherapy

NCT07153445 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT07153445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07153445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Chemotherapy + Atezolizumab for Stage IIIa and IIIb Non-small Cell Lung Cancer Followed by Atezolizumab as Adjuvant Treatment After Surgery and Atezolizumab as Maintenance Treatment for Non-resected Patients After Chemoradiotherapy
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Recruiting
Start date
July 8, 2025
Completion date
May 2, 2035
Enrollment
97 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, stage iiia lung cancer, stage iiib lung cancer